Skip to main content
CDT logo

CDT Equity Inc. (CDT) Stock Price & Analysis

CDT Equity Inc. (CDT) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $0.2671 (-22.13%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.2671 −$0.0759 (-22.13%)

CDT Equity Inc. · CDT

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetizing therapeutic assets.

Price as of Nov 19, 2026

Key Statistics

57 of 100

MoonshotScore v2 · CDT Equity (CDT)

Fair
Business Quality Elite (91)
Financial Safety Sound (73)
Valuation Fair (78)
Growth Durability Growing (70)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry, and the price trend has turned against it. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Falling.

  • quarterly revenue $750M (Q2 FY2026, quarter ended Jun 30, 2026)
  • Altman Z 11.46 · Piotroski F 5
  • ROE 9.3% · ROA 2.6% · current ratio 2.14

Holding back: weak price trend

Helping: business quality, balance-sheet strength, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CDT (57 recorded, newest six shown)
RecordedScoreBand
43Weak
45Fair
44Weak
44Weak
57Fair
57Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$0.2671
Change on the day-22.13%
52-week range$0.2671 – $291250.00
Price / earnings (trailing)0.00
Shares traded on the day2.44M

Price & events

Other perspectives

Council score for CDT Equity (CDT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Moderate
Growth Durability Moderate
Momentum Negative

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Weak
ROE Weak
Gross Margin Neutral

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is CDT Equity (CDT), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CDT Equity Inc. (CDT) is the company analyzed here. It employs 4 people and is led by Jamie Bligh. In Q2 FY2026 it reported revenue of $750M and net income of $69M.

2 · Latest results

What do the latest results show for CDT Equity (CDT)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $750M.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$750M$69M-$8.71 (diluted)
Q1 FY2026$696M$51M-$55.62 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CDT Equity (CDT)?

Short answer · as of

The MoonshotScore pillars rate business quality, balance-sheet strength, an attractive price, durable growth as strengths. What is holding it back is weak price trend. The distress and quality screens read Altman Z 11.46 · Piotroski F 5. Trailing ratios: ROE 9.3% · ROA 2.6% · current ratio 2.14.

5 · Peer comparison

How does CDT Equity compare with its peers?

Short answer

CDT Equity's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Same industry, near in market value$39.43 Nov 18, 2026$174B87 5-pillar Nov 18, 2026
CDT Equity (CDT) — this page$0.2671—57

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 28, 2026

Transactions
8
Identified insiders
2
Purchases
0
Sales
5
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CDT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CDT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about CDT Equity (CDT)?

Read these with our analysis →

What Investors Ask About CDT Equity (CDT)

These answers are editorial: 1 of these 9 answers is drawn from the CDT research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CDT?

CDT carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CDT a good stock to buy?

Stock Expert AI does not rate CDT buy, sell or hold. CDT Equity Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CDT stock price today?

The last price recorded for CDT Equity Inc. (CDT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does CDT Equity Inc.'s data-driven approach differentiate it in the biopharmaceutical sector?

CDT Equity Inc. emphasizes a data-driven approach to differentiate itself in the highly competitive biopharmaceutical sector. This methodology is central to its strategy of identifying, enhancing, and monetizing therapeutic assets.

What are the key factors to evaluate for CDT?

CDT Equity Inc. (CDT) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Leveraging Data-Driven Approach for Asset Identification: The company's self-description as "data-driven" suggests a core competency in efficiently identifying and enhancing therapeutic assets. Not financial advice.

How frequently does CDT data refresh on this page?

CDT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CDT's recent stock price performance?

CDT Equity Inc. (CDT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified biopharmaceutical pipeline addressing multiple therapeutic areas (autoimmune, diabetes, infertility). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CDT overvalued or undervalued right now?

The trailing P/E of CDT Equity Inc. (CDT) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CDT before investing?

Before investing in CDT Equity Inc. (CDT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.